Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Headaches in multiple sclerosis: Cross-sectional study of a multiethnic population.
The quality of reports of randomized trials in multiple sclerosis: a review.
Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis.
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Genes associated with T helper 17 cell differentiation and function.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL
A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Breastfeeding is not related to postpartum relapses in multiple sclerosis.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination.
Estrogen and testosterone therapies in multiple sclerosis.
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice.
The value of qualitative and quantitative assessment of lesion to cerebral cortex signal ratio on double inversion recovery sequence in the differentiation of demyelinating plaques from non-specific T2 hyperintensities.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Age-related and cuprizone-induced changes in myelin and transcription factor gene expression and in oligodendrocyte cell densities in the rostral corpus callosum of mice.

Pages